Top Health News

NEW YORK (Reuters Health) – Contrary to early signs that women on the Pill hit a higher venture of hunch disease, a newborn look at the scrutiny literature found no link between hunch attacks and the so-called mini-pills.

Such pills, including brands like anovulant and Ovrette, include the catecholamine progestin, but not the oestrogen of traditional relationship curb pills. The results also held for other progestin-only relationship curb products, much as implants and shots.

"I conceive this is rattling reassuring that there is no accumulated venture of hunch attack," said Chrisandra Shufelt of the Women's Heart Center at Cedars-Sinai Medical Center, who was not participating in the review.

Millions of women worldwide verify progestin-only contraceptives. While combined contraceptives, which blend progestogen and estrogen, are more popular, their safety is ease a matter of debate, Shufelt said. Two reviews of early research, for instance, found roughly twice the venture of hunch attack among women on the Pill compared to those not on relationship control.

Just digit out of a meg healthy women in their early 30s actually undergo a hunch attack, however, so modify doubling that venture ease wouldn't amount to much.

Still, women at accumulated venture of hunch disease, much as heavy smokers or those with high blood pressure, might consider change to mini-pills or additional progestin-only product, said Dr. Genevieve Plu-Bureau, who led the review.

"In women without cardiovascular venture factors, I do not conceive that this alter would be necessary," Plu-Bureau, at the Hotel-Dieu Hospital in Paris, additional in an e-mail to Reuters Health.

The newborn work, published in the Journal of Clinical Endocrinology and Metabolism, is supported on results from six preceding studies that examined hunch attack venture in women on progestin-only relationship control.

The studies included more than 1,800 women older 16 to 44 eld on relationship curb and compared those to women not attractive the hormones.

It's the first analyse to focus on mini-pills, which ofttimes outlay more than $50 per month, and it does hit limitations. For instance, Plu-Bureau said the number of women was small, and her assemble didn't removed them supported on the pane of catecholamine or the identify of progestogen they took.

SOURCE: http://bit.ly/i5gRIZ The Journal of Clinical Endocrinology & Metabolism, online Feb 2, 2011.

Source